Influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province

DAI Se-ying; LIU Ai-wen; SHEN Yue-lan; CHENG Xiao-li; ZHANG Jin; WU Jian-jun; WU Jia-bin; XING Hui; RUAN Yu-hua

doi:10.16462/j.cnki.zhjbkz.2022.12.003

Volume 26 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(12): 1379-1383

DAI Se-ying, LIU Ai-wen, SHEN Yue-lan, CHENG Xiao-li, ZHANG Jin, WU Jian-jun, WU Jia-bin, XING Hui, RUAN Yu-hua. Influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1379-1383. doi: 10.16462/j.cnki.zhjbkz.2022.12.003

Citation:

DAI Se-ying, LIU Ai-wen, SHEN Yue-lan, CHENG Xiao-li, ZHANG Jin, WU Jian-jun, WU Jia-bin, XING Hui, RUAN Yu-hua. Influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1379-1383. doi: 10.16462/j.cnki.zhjbkz.2022.12.003

Citation:

DAI Se-ying, LIU Ai-wen, SHEN Yue-lan, CHENG Xiao-li, ZHANG Jin, WU Jian-jun, WU Jia-bin, XING Hui, RUAN Yu-hua. Influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1379-1383. doi: 10.16462/j.cnki.zhjbkz.2022.12.003

PDF( 933 KB)

Influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province

doi: 10.16462/j.cnki.zhjbkz.2022.12.003

DAI Se-ying^{1, 2},
LIU Ai-wen^{1, 2},
SHEN Yue-lan^{1, 2},
CHENG Xiao-li^{1, 2},
ZHANG Jin^{1, 2
,
,},
WU Jian-jun^{1, 2},
WU Jia-bin^{1, 2},
XING Hui³,
RUAN Yu-hua³

1.
Department of AIDS prevention, Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China
2.
Center Laboratory of HIV Molecular and Immunology, Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China
3.
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

DAI Se-ying, LIU Ai-wen and SHEN Yue-lan contributed equally to this article

Funds:

National Science and Technology Major Projects of China 2017ZX10201101

More Information

Corresponding author: Zhang Jin, E-mail: zhangjin@ahcdc.com.cn
Received Date: 2021-09-24
Rev Recd Date: 2022-01-22

Available Online: 2022-12-30

Publish Date: 2022-12-10

Abstract

Abstract

Objective To understand the influencing factors on the death of HIV/AIDS patients receiving antiretroviral therapy in Anhui Province. Methods A 1 to 2 matched case-control study was conducted to collect the information of HIV/AIDS patients who received antiretroviral therapy in Anhui Province from 2010 to 2019. The conditional logistic regression was used to analyze the risk factors on the death of HIV/AIDS patients. Results A total of 4 347 HIV/AIDS patients were investigated, with 1 449 cases in the death group and 2 898 cases in the control group. The multivariate conditional logistic regression result showed that among the death risk factors, drug resistance was 1.75 times (95% CI: 1.22-2.52, P=0.003) than that of non-drug resistance; the latest viral load ≥1 000 copies/mL and non-drug resistance tested results were 2.26 times (95% CI: 1.69-3.03, P < 0.001) than that of non-drug resistance; non-viral load and non-drug resistance tested results were 35.27 times (95% CI: 26.54-46.87, P < 0.001) than that of non-drug resistance; patients who age 30-49 years old was 1.40 times (95% CI: 1.01-1.94, P=0.042) than that of the 18-29 years old, and those age ≥ 50 years old was 4.02 times (95% CI: 2.80-5.77, P < 0.001) that of 18-29 years old; male was 1.37 times (95% CI: 1.08-1.74, P=0.011) than that of female, the transmission route of injecting drug use was 6.27 times (95% CI: 2.00-19.61, P=0.002) than that of heterosexual transmission; WHO clinical stage Ⅲ/Ⅳ before treatment was 1.41 times (95% CI: 1.12-1.76, P=0.007) than that of stage Ⅰ/Ⅱ; CD4⁺T lymphocyte count < 200 cells/μL before treatment was 1.95 times (95% CI: 1.50-2.54, P < 0.001) that of CD4⁺≥350 cells/μL before treatment. Conclusions Drug resistance, drug resistance test after antiretroviral therapy, age, gender, transmission route, WHO clinical stage before treatment, and CD4⁺T lymphocyte counts before treatment were the influencing factors of HIV/AIDS death in Anhui Province. Strengthening the monitoring of drug resistance for HIV/AIDS patients is important for reducing AIDS deaths. It is necessary to test viral load and drug resistance in time for HIV/AIDS patients receiving antiretroviral therapy.
- HIV,
- Death,
- Influencing factors,
- Case-control study

FullText(HTML)

References(13)

References

[1]	郝阳, 崔岩, 孙新华, 等. "四免一关怀"政策实施十年来中国艾滋病疫情变化及特征分析[J]. 中华疾病控制杂志, 2014, 18(5): 369-374. https://zhjbkz.ahmu.edu.cn/article/id/JBKZ201405001 Hao Y, Cui Y, Sun XH, et al. A retrospective study of HIV/AIDS situation: a ten-year implementation of"four frees and one care"policy in China[J]. Chin J Dis Control Prev, 2014, 18(5): 369-374. https://zhjbkz.ahmu.edu.cn/article/id/JBKZ201405001
[2]	国家卫生健康委员会疾病预防控制局. 2019年我国艾滋病防治工作取得新进展[J]. 中国艾滋病性病, 2019, 25(12): 1205. DOI: 10.13419/j.cnki.aids.2019.12.01. Disease Control and Prevention Bureau of National Health Commission. New progress in AIDS prevention and control of China in 2019[J]. Chin J AIDS STD, 2019, 25(12): 1205. DOI: 10.13419/j.cnki.aids.2019.12.01.
[3]	温兰, 杨晓辉, 沈月兰. 阜阳市HIV抗病毒治疗患者耐药情况分析[J]. 安徽预防医学杂志, 2018, 24(3): 179-183. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYF201803007.htm Wen L, Yang XH, Shen YL. Analysis of drug resistance in patients with HIV antiviral therapy in Fuyang City[J]. Anhui J Prev Med, 2018, 24(3): 179-183. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYF201803007.htm
[4]	Zhang TH, Liao LJ, Shao YM, et al. Relationship between drug resistance and death in HIV-infected patients receiving antiretroviral therapy-7 PLADs, China, 2010-2019[J]. China CDC Weekly, 2021, 3(14): 291-297. DOI: 10.46234/ccdcw2021.068.
[5]	沈月兰, 苏斌. HIV-1获得性耐药研究进展[J]. 安徽预防医学杂志, 2019, 25(2): 123-127. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYF201902012.htm Shen YL, Su B. Progress in acquired drug resistance of HIV-1[J]. Anhui J Prev Med, 2019, 25(2): 123-127. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYF201902012.htm
[6]	Gupta-Wright A, Fielding K, van Oosterhout JJ, et al. Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study[J]. Lancet HIV, 2020, 7(9): 620-628. DOI: 10.1016/S2352-3018(20)30172-7.
[7]	周玚, 梁姝, 李一平, 等. 凉山彝族自治州布拖县2010-2019年抗病毒治疗HIV/AIDS死亡的影响因素分析[J]. 中华流行病学杂志, 2021, 42(5): 886-890. DOI: 10.3760/cma.j.cn112338-20200902-01115. Zhou C, Liang S, Li YP, et al. Influencing factors on the death of HIV/AIDS patients treated with antiviral treatment in Butuo county, Liangshan Yi Autonomous Prefecture, 2010-2019[J]. Chin J Epidemiol, 2021, 42(5): 886-890. DOI: 10.3760/cma.j.cn112338-20200902-01115.
[8]	虞玲, 隋俊, 黄菁. HAART治疗AIDS患者基线CD4⁺细胞水平对免疫重建效果的预测价值[J]. 公共卫生与预防医学, 2020, 31(2): 58-61. DOI: 10.3969/j.issn.1006-2483.2020.02.014. Yu L, Sui J, Huang J. Predictive value of baseline CD4⁺ Cell Counts and CD4/CD8 ratio in immune reconstitution in HIV/AIDS patients receiving highly effective antiretroviral therapy[J]. J Pub Health and Prev Med, 2020, 31(2): 58-61. DOI: 10.3969/j.issn.1006-2483.2020.02.014.
[9]	蔡畅, 汤后林, 李东民, 等. 我国艾滋病患者的死亡趋势及其相关危险因素分析[J]. 中华流行病学杂志, 2021, 42(1): 121-125. DOI: 10.3760/cma.j.cn112338-20200918-01169. Cai C, Tang HL, Li DM, et al. Analysis on death trend in AIDS patients and related risk factors in China[J]. Chin J Epidemiol, 2021, 42(1): 121-125. DOI: 10.3760/cma.j.cn112338-20200918-01169.
[10]	Sheehan DM, Trepka MJ, Fennie KP, et al. Individual and neighborhood determinants of late HIV diagnosis among latinos, Florida, 2007-2011[J]. J Immigr Minor Health, 2017, 9(4): 825-834. DOI: 10.1007/s10903-016-0422-2.
[11]	罗艳, 赵刚, 黄思超, 等. 2013-2018年杭州市HIV/AIDS病例检测发现与晚发现影响因素研究[J]. 预防医学, 2020, 32(8): 757-761. DOI: 10.19485/j.cnki.issn2096-5087.2020.08.001. Luo Y, Zhao G, Huang SC, et al. HIV/AIDS case detection and influencing factors for late diagnosis in Hangzhou from 2013 to 2018[J]. Prev Med, 2020, 32(8): 757-761. DOI: 10.19485/j.cnki.issn2096-5087.2020.08.001.
[12]	陈洋, 宋晓甜, 姚永明, 等. 贵州省1996-2015年注射吸毒人群HIV/AIDS死亡率及其影响因素分析[J]. 中华流行病学杂志, 2019, 40(7): 765-769. DOI: 10.3760/cma.j.issn.0524-6450.2019.07.006. Chen Y, Song XT, Yao YM, et al. Mortality and influencing factors on injecting drug users with HIV/AIDS in Guizhou province, 1996-2015[J]. Chin J Epidemiol, 2019, 40(7): 765-769. DOI: 10.3760/cma.j.issn.0524-6450.2019.07.006.
[13]	Croxford S, Miller RF, Post FA, et al. Cause of death among HIV patients in London in 2016[J]. HIV Med, 2019, 20(9): 628-633. DOI: 10.1111/hiv.12761.